Q1 2026 Siemens Healthineers AG Earnings Call Transcript
Key Points
- Siemens Healthineers AG (SMMNY) reported strong operational performance in Imaging and Precision Therapy, with a 6% growth and an operational margin expansion that compensated for tariffs and FX headwinds.
- The company received a strong investment-grade rating from Moody's, marking a milestone for financial independence and demonstrating financial strength.
- The Atellica franchise in Diagnostics grew by roughly 20% in Q1, now accounting for almost 70% of sales in the core lab solution business.
- Siemens Healthineers AG (SMMNY) entered a new 10-year value partnership with Onvida, expected to exceed $100 million in total value, enhancing rural health and quality of care.
- The company's Elevating Health Globally strategy is gaining traction, with positive feedback from customers and partners, particularly in the fight against non-communicable diseases.
- Diagnostics segment faced a revenue decline of 3%, primarily due to market challenges in China, including volume-based procurement and reimbursement reductions.
- The company expects revenue growth for Q2 to be below the outlook range of 5% to 6%, with Diagnostics continuing to face challenges in China.
- Tariffs and foreign exchange headwinds significantly impacted margins, with a disclosed adjusted EBIT margin of 15%, flat year over year.
- The Precision Therapy segment, despite strong growth, is expected to see a margin decline in Q2 due to tariffs, FX, and special items in Q1.
- Siemens Healthineers AG (SMMNY) anticipates ongoing market challenges in China for Diagnostics, leading to a more pronounced revenue decline in Q2 compared to Q1.
Good morning, ladies and gentlemen, and welcome to Siemens Healthineers' conference call. As a reminder, this conference is being recorded.
Before we begin, I would like to draw your attention to the Safe Harbor statement on page 2 of the Siemens Healthineers presentation. This conference call may include forward-looking statements. These statements are based on the company's current expectations and certain assumptions and are, therefore, subject to certain risks and uncertainties.
At this time, I would like to turn the call over to your host today, Mr. Marc Koebernick, Head of Investor Relations. Please go ahead, sir.
Thank you, operator. Good morning, and welcome, everyone, to our Q1 earnings call for fiscal 2026. I'd like to thank each one of you for joining us today.
At 7:00 this morning, we published our Q1 2026 results. All related material for today's results release are available on the IR section of the Siemens Healthineers' web page.
In a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
